INGELHEIM, Germany--(BUSINESS WIRE)--For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCITM.1 The study will evaluate the efficacy and safety of the oral anticoagulant dabigatran etexilate in patients with an irregular heartbeat called non-valvular atrial fibrillation (AF), who have undergone a percutaneous coronary intervention (PCI) with stent placement to widen their blocked coronary arteries.2 RE-DUAL PCITM aims to advance medical knowledge and guide future antithrombotic treatment choice for greatest patient benefit. It addresses the need for innovative new treatment regimens to improve patient prognosis.
Help employers find you! Check out all the jobs and post your resume.
